New research reveals that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who end conventional lifestyle regimens.
Research printed in a major health publication demonstrates that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"People buying such drugs need to be informed of the risk of fast rebound weight gain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to original mass in about one and a half years.
Weighing Approaches
The analysis, which reviewed 37 of trials involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with older methods.
The team emphasize that people who shed pounds through lifestyle changes alone typically see a less rapid creep back—around 100 grams monthly—post-intervention.
Understanding the Quick Rebound
Nutrition scientists propose the way of the injections accounts for the heightened regain.
The injections copy a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this medication results in appetite is no longer kept in check, making overeating a significant risk."
A Chronic Condition?
The NHS advise the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals contend that, given the high risk of weight regain, the therapy should be considered long-term.
This view is supported by drug manufacturers, who say that the findings "underscore the persistent nature of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
People who have come off the jabs report a powerful resurgence of hunger.
"It felt as if a trigger flipping and you're instantly ravenous," said one woman.
The struggle is compounded if patients have not developed sustainable dietary or behavioural modifications during therapy.
Significant Use
Figures suggest that millions of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Adoption is greater among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while the jabs are powerful agents for weight loss, they are not a standalone fix and maintained weight loss hinges on ongoing lifestyle support.
